Repare Therapeutics Inc. (RPTX) News
Filter RPTX News Items
RPTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RPTX News Highlights
- For RPTX, its 30 day story count is now at 10.
- Over the past 28 days, the trend for RPTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RPTX are AC and ATR.
Latest RPTX News From Around the Web
Below are the latest news stories about REPARE THERAPEUTICS INC that investors may wish to consider to help them evaluate RPTX as an investment opportunity.
Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination TrialsRepare Therapeutics Inc (NASDAQ: RPTX) reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) in molecularly selected advanced solid tumors. Preliminary antitumor activity was observed, including moderate tumor shrinkages and a confirmed partial response. Several patients demonstrated long stable disease and remained on treatment for greater than 11 months and ongoing. Early clinical combination insights demonstrated greater antitumor ac |
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare ConferenceCAMBRIDGE, Mass. & MONTREAL, June 08, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time in Dana Point, California. |
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination TrialsCAMBRIDGE, Mass. & MONTREAL, June 07, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported initial proof of concept monotherapy data from its Phase 1 MYTHIC clinical trial evaluating lunresertib (RP-6306), a first-in-class, oral PKMYT1 inhibitor in molecularly selected advanced solid tumors. |
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid TumorsCAMBRIDGE, Mass. & MONTREAL, June 06, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that data from the ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), were published in Nature Medicine. |
Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap touched US$481m last week, benefiting both private equity firms who own 34% as well as institutionsKey Insights Significant control over Repare Therapeutics by private equity firms implies that the general public has... |
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials InsightsCAMBRIDGE, Mass. & MONTREAL, June 02, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kin |
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass. & MONTREAL, May 22, 2023--Repare Therapeutics Inc., (Nasdaq: RPTX), ("Repare", or "the Company"), a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company’s EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company’s common shares. The award was approved by the Compensation Committee of the Company’s Board of Directors |
Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%Repare Therapeutics Inc. ( NASDAQ:RPTX ) shareholders will have a reason to smile today, with the analysts making... |
Earnings Update: Repare Therapeutics Inc. (NASDAQ:RPTX) Just Reported And Analysts Are Boosting Their EstimatesRepare Therapeutics Inc. ( NASDAQ:RPTX ) just released its latest quarterly report and things are not looking great... |
A Look At The Intrinsic Value Of Repare Therapeutics Inc. (NASDAQ:RPTX)Key Insights Repare Therapeutics' estimated fair value is US$9.29 based on 2 Stage Free Cash Flow to Equity Current... |